Mitochondrial Dysfunction Drives Oxidative Stress and Energy Imbalance in a Murine Model of Spondyloarthritis

Rodrigo Prieto-Carrasco1, Susana Aideé González-Chávez1, Eduardo Chaparro-Barrera1

  • 1PABIOM Laboratory, Faculty of Medicine and Biomedical Sciences, Autonomous University of Chihuahua, Chihuahua, Mexico.

PubMed

Insights

Mitochondrial dysfunction drives joint damage in spondyloarthritis (SpA). This study reveals altered mitochondrial dynamics, reduced energy production, and increased oxidative stress in SpA, suggesting new therapeutic targets.

Area of Science:

  • Immunology
  • Mitochondrial Biology
  • Rheumatology

Background:

  • Spondyloarthritis (SpA) pathogenesis involves joint inflammation and damage not fully explained by current immune models.
  • Mitochondrial dysfunction is implicated in other rheumatic diseases, but its role in SpA is unclear.

Purpose of the Study:

  • To comprehensively investigate mitochondrial alterations in a murine model of spontaneous arthritis (SpAD).
  • To assess mitochondrial dynamics, bioenergetics, oxidative stress, and transcriptomic changes in SpA joint tissues and cells.

Main Methods:

  • Comparison of SpAD mice with healthy controls (BALB/c mice).
  • Analysis of joint tissues, isolated mitochondria, and cultured fibroblast-like synoviocytes (FLS).
  • Assessment of mitochondrial dynamics (fission/fusion), turnover (biogenesis/mitophagy), bioenergetics, oxidative stress markers, and gene expression.

Main Results:

  • SpAD mice exhibited coordinated mitochondrial dysfunction, including increased fission, reduced fusion, and dysregulated turnover.
  • Impaired mitochondrial complex activity, reduced ATP production, and elevated oxidative stress were observed.
  • Transcriptomic analysis revealed significant changes in mitochondrial function-related genes, confirming dysregulation in SpAD.

Conclusions:

  • Mitochondrial dysfunction is a key feature of SpA pathophysiology in this model, potentially driving joint damage.
  • Targeting mitochondrial pathways presents a novel therapeutic strategy for spondyloarthritis disease modification.